title: Renal sympathetic nerve denervation for the treatment of resistant hypertension.
abstract: Improvements in BP control with pharmacotherapy undoubtedly translate into significant individual and population health benefits. RDN results in impressive reductions in BP, which are likely to be associated with further improvements in clinical outcomes. With more clinical trials and concurrent development of new devices, we hope that RDN holds up to its current accolades.
authors.affiliation: Department of Cardiology, Cardiac Investigation Unit, St Vincent's Hospital, Melbourne, VIC. sonny.palmer@svhm.org.au
authors.forename: Sonny C
authors.initials: SC
authors.lastname: Palmer
authors.forename: Christopher
authors.initials: C
authors.lastname: Judkins
authors.forename: Paul D
authors.initials: PD
authors.lastname: Williams
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Whitbourn
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001315:Australia; D001795:Blood Pressure Determination / Q000379:methods; D017115:Catheter Ablation / Q000379:methods*; D018450:Disease Progression; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D007668:Kidney / Q000294:innervation*; D008297:Male; D061214:Patient Safety; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D013562:Sympathectomy / Q000379:methods*; D013564:Sympathetic Nervous System / Q000601:surgery; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents